Specialist cancer drug discovery company, Sareum, and oncology-focused development and commercialisation company, Cancer Research Technology Limited, last week announced the publication of the latest results from their joint research collaboration with The Institute of Cancer Research. The results were presented at the National Cancer Research Institute Cancer Conference, in Birmingham, UK.

Of particular interest was data showing how the drug candidate Chk1 (Checkpoint Kinase 1) can produce up to twofold increases in the efficacy of marketed cancer chemotherapeutics.

Sareum is developing seven early-stage cancer drug programmes, one of which is ready for licensing and two are close to licensing. Chk1 is the most advanced and we believe that, as with some other Sareum cancer programmes, it is attracting interest from potential licensees.

Major pharmaceuticals groups have a well-known need to build their cancer drug pipelines and to bring drugs to market quickly. We believe Sareum can be expected to react even more positively to any good news, particularly were the company to sign a deal.

yeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeehaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
kerrrrrrrrrrrrrrrrrrchingggggggggggggggggggggaroooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooo

gla